Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ: DXCM )

89.07 +4.98 (+5.92%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
If You Invested $1000 In DexCom 10 Years Ago, Here's How Much You Would Have Today
DexCom (NASDAQ:DXCM) has outperformed the market over the past 10 years by 32.66% on an annualized basis producing an average annual return of 44.4%. Currently, DexCom has a market capitalization of... 
Via Benzinga
Read Here Why Did This Analyst Cut DexCom's Price Target
Via Benzinga
Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review
The Nasdaq hit its lowest level since 2020. Apple and Facebook led key earnings. 
Via Investor's Business Daily
Dexcom Updates First Quarter 2022 Conference Call for April 28, 2022 at 5:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
Dexcom Stock Ticks Lower On Mixed First-Quarter Report
Dexcom dipped on light first-quarter profit, though sales narrowly beat forecasts. 
Via Investor's Business Daily
Recap: DexCom Q1 Earnings
DexCom (NASDAQ:DXCM) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings DexCom missed estimated earnings by... 
Via Benzinga
Dexcom Reports First Quarter 2022 Financial Results
From DexCom, Inc.
Via Business Wire
Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes
Insulet Corporation (NASDAQ: PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with... 
Via Benzinga
DexCom Showcases Expanded CGM Portfolio at International ATTD Conference, Offering More Choice to People With Diabetes
From DexCom, Inc.
Via Business Wire
DexCom Stock Falls As Q4 Profit, FY22 Sales Outlook Trail Wall Street Estimates
DexCom Inc's (NASDAQ: DXCM)  
Via Benzinga
Markets Fall Sharply Amid Ongoing Rate Hike Concerns
The S&P 500 traded lower for the third week in a row as investors brace for a potential 0.5% interest rate hike by the Federal Reserve. U.S. indices traded sharply lower... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Dexcom Publishes Annual Sustainability Report
From DexCom, Inc.
Via Business Wire
Here's How Much $100 Invested In DexCom 5 Years Ago Would Be Worth Today
DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 32.15% on an annualized basis producing an average annual return of 45.92%. Currently, DexCom has a market capitalization of... 
Via Benzinga
3 Top S&P 500 Stock Market Gainers Today: Medicals Lead As This Sector Reverses Hard
Medical and gold stocks led the S&P 500. Transport stocks were big losers. 
Via Investor's Business Daily
Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
Dexcom Stock Shows Market Leadership With Jump To 86 RS Rating
Dexcom shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
Markets Have Another Strong Week As S&P 500 Erases Initial Losses From Russia-Ukraine War
U.S. indices finished mixed Friday to conclude the trading week. Oil prices gained during Friday's session, which has continued to pressure economic sentiment. The S... 
Via Benzinga
Dexcom Announces Four-for-One Forward Stock Split
From DexCom, Inc.
Via Business Wire
Markets Fall In Anticipation Of This Week's Fed Decision
U.S. indices finished lower Monday amid continued Russia-Ukraine uncertainty, as well as in anticipation of this week’s Fed decision. The Nasdaq composite finished lower by... 
Via Benzinga
Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management
From DexCom, Inc.
Via Business Wire
Dexcom Snags A New Diabetes Device Win After Covid-Related Delay
Dexcom won out in Europe after the pandemic slowed its G7 CGM. 
Via Investor's Business Daily
Dexcom G7 Continuous Glucose Monitoring System Receives European CE Mark
DexCom Inc's (NASDAQ: DXCM) Dexcom G7 Continuous Glucose Monitoring (CGM) System has secured European CE Mark for people with diabetes aged two years and older... 
Via Benzinga
Could A Simple Device Help Revolutionize Medical Diagnostics? This Company Thinks So
Image provided by Know Labs This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Know... 
Via Benzinga
DexCom's Glucose Monitoring System Snags Breakthrough Device Tag For Hospital Use
The FDA granted Breakthrough Device Designation for DexCom Inc (NASDAQ: DXCM) for continuous glucose monitoring (CGM) use in the hospital setting. Dexcom CGM... 
Via Benzinga
Dexcom Announces Upcoming Virtual Conference Presentations
From DexCom, Inc.
Via Business Wire
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-... 
Via Benzinga
Recap: DexCom Q4 Earnings
DexCom (NASDAQ:DXCM) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings DexCom missed estimated earnings by... 
Via Benzinga
Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results
From DexCom, Inc.
Via Business Wire
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.